NASDAQ: HRMY · Biotechnology
Harmony Biosciences (HRMY) fair value and price range
As of 14 Nov 2026, Faircurve's model values Harmony Biosciences (HRMY) at $33.93 a share. The stock last closed at $32.96, which puts the model's fair value 2.9% above the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
Revalued . Price is the close of 16 Nov 2026. Harmony Biosciences Holdings, Inc.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 moved the fair value from $33.28 to $33.93 (+2.0%). The multiple the model anchors on moved, lifting the fair value: most of the move.
What the model makes of itThe price of $32.96 is 2.9% below it. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What's nextNext report on 23 Feb 2027. Options prices imply a move of about 15% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give HRMY?
The calibrated range for HRMY over 63 trading days is $27.74 to $39.51. It sits around the last close, and its width comes from the volatility that HRMY's own options imply (52% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $25.67 to $45.26. In 50% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm that develops and markets therapies for people in the United States with rare neurological conditions.
Faircurve's model gave a fair value of $33.93 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $33.28, so the fair value moved +2.0%. In the model's own words, "The multiple the model anchors on moved, lifting the fair value: most of the move." The calibrated range over 63 trading days is $28.96 to $39.66, built around the price from the volatility the stock's own options imply. That range is calibrated weekly against realised prices, using 8,038 past valuations, refreshed 14 Nov 2026. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say whether the fair value is right.
The sheet for this run gives no quality score for the business, so no quality comparison with peers can be stated. The model compares Harmony with four companies that each have a fair value of their own on the site: Fortrea Holdings Inc. (FTRE), Vericel Corporation (VCEL), and ADMA Biologics, Inc. (ADMA). Five further comparable companies have no verdict on this date: Sarepta Therapeutics, Inc. (SRPT), Vir Biotechnology, Inc. (VIR), Arcus Biosciences, Inc. (RCUS), Xencor, Inc. (XNCR), and Innoviva, Inc. (INVA).
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does HRMY report earnings, and how has the stock reacted?
Harmony Biosciences's next earnings report is scheduled for 23 Feb 2027. Companies can move their dates.
Options prices on 16 Nov 2026 imply a move of about 12.2% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. HRMY's 30 day implied volatility works out to about 15.1% over one month.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across HRMY's last 8 reports, ignoring direction, was 6.2%.
What the options market has priced for a month's move in HRMY
How does HRMY compare with similar companies?
The companies in biotechnology closest to Harmony Biosciences in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| FTRE Fortrea Holdings Inc. | $19.79 | $24.79 | +25.3% | Undervalued |
| SRPT Sarepta Therapeutics, Inc. | $15.13 | $19.51 | +28.9% | Low evidence grade |
| VIR Vir Biotechnology, Inc. | $9.58 | $9.51 | -0.7% | Low evidence grade |
| RCUS Arcus Biosciences, Inc. | $16.86 | $16.32 | -3.2% | Low evidence grade |
| XNCR Xencor, Inc. | $35.40 | $35.72 | +0.9% | Low evidence grade |
| INVA Innoviva, Inc. | $18.49 | $19.11 | +3.4% | Low evidence grade |
| VCEL Vericel Corporation | $57.48 | $65.96 | +14.8% | Fairly valued |
| ADMA ADMA Biologics, Inc. | $13.47 | $15.96 | +18.5% | Undervalued |
Harmony Biosciences at a glance
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions.
- Market value
- $2.0B
- Sector
- Healthcare
- Industry
- Biotechnology
- Revenue expected, next twelve months
- $1.2B
- Consensus revenue growth, next fiscal year
- +18.4%
- Analysts with estimates
- 7
- Beta to the US market
- 0.60
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices Harmony Biosciences on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for HRMY was $33.28. As of 14 Nov 2026 it is $33.93, a change of +2.0%. The multiple the model anchors on moved, lifting the fair value: most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Harmony Biosciences's valuation
Is Harmony Biosciences stock undervalued or overvalued?
Faircurve's model puts HRMY's fair value at $33.93 a share against a last close of $32.96, as of 14 Nov 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What is HRMY's fair value?
$33.93 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $25.67 to $45.26.
What price range does the model give HRMY?
$27.74 to $39.51 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does Harmony Biosciences report earnings next?
The next report is scheduled for 23 Feb 2027. Companies can move their dates.
How much has HRMY moved on past earnings reports?
Across its last 8 reports the median two session move was 6.2%, ignoring direction. The largest was -12.3% around the report of 4 Nov 2026.
How confident is the model in this valuation?
The model's evidence grade for HRMY is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on HRMY
The model holds no idea open on HRMY today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on HRMY with their outcomes. A free account is enough.